A range of malignancies, including ovarian, breast, colorectal, and endometrial cancers, frequently exhibit activation of the PI3K pathway through various mechanisms, including genomic mutations or alterations involving PIK3CA, PIK3R1, PTEN, AKT, TSC1, TSC2, LKB1 (also known as STK11), MTOR, and other oncogenes or tumor suppressor genes [16, 17]. This evidence concerns the gene STK11 and endometrial cancer.